39 results about "Psychoactive substance" patented technology

A method of identifying individuals impaired by a psychoactive substance such as cannabis. The method includes presenting monocularly to a subject being tested; to each eye separately, a sinusoidal grating pattern of fixed spatial frequency with achromatic contrast or color contrast between grating stripes being temporally alternately modulated at a temporal frequency that ranges between 10 Hz and 60 Hz with a pattern of the contrast being such that the subject being tested can see a frequency doubling in the grating pattern.

The invention provides a surface-enhanced Raman scattering (SERS) method for rapidly detecting new psychoactive substances in human urine, which comprises the following steps: synthesizing gold nanorod colloidal sols with SERS activity; dripping the cleaned gold nanorod colloidal sols onto a clean hydrophobic silicon wafer, and drying to obtain an SERS substrate; collecting human urine, adding a nitric acid solution, shaking, and standing for 4-6 min; adding a slightly alkaline solution and an organic extractant, and carrying out shaking extraction; standing for 1-2 min, and collecting an organic layer solution; and dripping the organic layer solution onto the SERS substrate, and performing SERS detection with a portable Raman spectrometer. Through pretreatment of toxins in human urine, the method disclosed by the invention can rapidly purify and enrich new psychoactive substances in human urine, and the detection is sensitive and rapid and can be completed within 10 min.

The invention discloses a method for analyzing 37 fentanyl new psychoactive substances in hair. The method comprises the following steps: (1) preparing a solution; (2) preparing a sample; and (3) carrying out liquid chromatography-tandem mass spectrometry analysis on a to-be-detected sample solution, a to-be-detected standard curve solution and a to-be-detected blank solution prepared in the step(2), and establishing an analysis method for determining 37 fentanyl new psychoactive substances in the sample solution. The high-sensitivity and high-selectivity HPLC-MS / MS qualitative and quantitative analysis method is established by taking fentanyl new psychoactive substances as research objects and hair as a biological detection material, and is applied to detection and analysis of specific cases so that related technical support is provided for related fields such as judicial expertise and the like.

Disclosed is a new antibody which can be used to relieve addiction caused by nerve active substances, including opium, cocaine, benzedrine, ketamine, etc. Cocain and amphetamine-regulated transcript peptide antibody gene is selected through phage display technology; then single-chain antibody sequence of the cocain and amphetamine-regulated transcript peptide(CART) and the procaryon expression vector are connected and are induced to express and to be purified to obtain single-chain antibody in response to CART, which is named as CARTscFv(AH1,AH4B,AH6,AH19,AH33B,AH36). Injecteion of CARTscFv into the abdominal cavity of a mouse, together with the CART at the peripheral circulation system, leads to the reduction of the CART in the central nervous system of the mouse. Animal model with behavioral sensitization induced by cocain proves that the CART single-chain antibody can restrain the expression of the behavioral sensitization of the mouse induced by cacain, which shows that the CART single-chain antibody is of great potential in curing addiction and particularly relapse caused by nerve active.

This invention relates to methods and devices for the detection and characterization of psychoactive compounds by analyzing alterations of network level physiological characteristics before and after the introduction of a candidate sample onto an in vitro neuronal tissue sample. The invention further provides a software package that enables an operator to deliver a timed electrical pulse to neuronal samples at a specific point in their spontaneous or induced oscillations. Such temporal stimulations trigger unexpected and useful network level physiological responses.

The invention provides an on-site rapid enrichment and purification device and method for psychoactive substance in a water environment. The device comprises a liquid storage bottle, a leacheate bottle, a first activation liquid bottle, a first liquid injection pump, an enrichment disc, an adsorption trap, a sample bottle, a second liquid injection pump, a waste liquid bottle and an elution device. The outlet of the liquid storage bottle and the outlet of the first liquid injection pump are respectively connected with an inlet pipeline of the enrichment disc; the leacheate bottle and the firstactivation liquid bottle are connected with an inlet pipeline of the first liquid injection pump; the outlet of the enrichment disc and the outlet of the second liquid injection pump are respectivelyconnected with an inlet pipeline of the adsorption trap; the sample bottle and the waste liquid bottle are respectively connected with an outlet pipeline of the adsorption trap; and the elution device is connected with an inlet pipeline of the second liquid injection pump. The device is simple in structure and reasonable in design; and when the device is used for pretreatment of the sample underthe field condition, the speed is fast, the energy consumption is low, and the operation is simple and convenient.

The invention discloses an isotope psychoactive substance labeling compound, and a preparation method and application thereof. The isotope psychoactive substance labeling compound provided by the invention can be used for an internal standard for measuring the content of a psychoactive substance methyl 2-(1-(5-p-fluorobenzyl)-indole-3-amide)-3, 3-dimethylbutyrate in a hair sample. methyl 2-(1-(5-p-fluorobenzyl)-indole-3-amide)-3, 3-dimethylbutyrate is subjected to qualitative detection according to the retention time and ion pair matching, and specifically, corresponding compounds are subjected to quantitative detection according to the chromatographic peak areas. When the isotope labeling compound is used as an internal standard substance, the matrix effect of a detected material can be reduced, and the isotope labeling compound has a good application prospect in the aspects of judicial expertise and the like.

The invention discloses a detection method of a new psychoactive substance MDBZP. The method, provided by the invention, for accurately and efficiently determining the MDBZP in biological samples comprises qualitative and quantitative analysis methods including gas chromatography-mass spectrometry, gas chromatography, liquid chromatography, liquid chromatography-mass spectrometry, and the like; the biological samples can be at least one of blood, urine, saliva and hair. Due to the large number of interfering factors in the biological samples, the pretreatment process of the tested materials isvery important. By means of a great number of experiments, the detection method effectively and fully extracts MDBZP in the biological samples by using a solid phase extraction process; the high-efficiency qualitative and quantitative analysis is realized; the analysis methods are high in sensitivity and wide in linear range. A detector is low in cost and beneficial to automatic analysis operation.

The invention discloses a universal detection method for opioid active substances and a detection kit thereof, the detection kit is divided into a detection group reagent and a control group reagent,the detection group reagent comprises a monoclonal cell line MOR1-copGFP / 293 for stably expressing a human mu opioid receptor MOR1 gene and intracellular free calcium ion detection fluorescent probe reagent Fura Red, and the reagent of the control group comprises a blank control monoclonal cell line copGFP / 293 and the intracellular free calcium ion detection fluorescent probe reagent Fura Red; thepreparation method of the blank control monoclonal cell line copGFP / 293 comprises the following steps of: performing co-transfection of pCDH-CMV-MCS-EF1-copGFP plasmids, pH1 plasmids and pH2 plasmidsto lentivirus packaging cells 293V to prepare EF1-copGFP lentivirus; and infecting human embryo kidney cells 293 with the copGFP lentivirus to obtain the blank control monoclonal cell line copGFP / 293. Accurate and high-sensitivity rapid detection of all opioid active substances can be achieved, and the problem that supervision of novel synthetic opioid psychiatric active substances is difficult can be solved.

Administering a therapeutically effective dose of lithium ions mitigates the side effects of a psychoactive substance such as a cannabinoid. The therapeutically effective dose of lithium ions includes greater than 4 milligrams of lithium and less than 170 milligrams of lithium, or includes between 8 and 32 milligrams of lithium ions per milligram of the psychoactive substance. The therapeutically effective dose of lithium ions is administered using lithium carbonate, lithium citrate, lithium chloride, lithium orotate, lithium aspartate, or analogs thereof using a delivery vehicle selected from pills, tablets, capsules, gelcaps, liquids, syrups, injectable liquids, powders, or foods and administered prior to, with, or after administration of the psychoactive substance. The psychoactive substance includes one or more of anandamide, 2-arachidonoyl glycerol, 2-arachidonoyl glycerol ether, tetrahydrocannabinol, cannabinol, cannabidiol, or analogs thereof and may be administered using the delivery vehicle.

The invention discloses a detection method of a novel psychoactive substance mCPP. The method for precisely and efficiently testing the mCPP in a biological sample comprises qualitative and quantitative analysis methods of gas chromatography mass spectrometry, gas phase chromatography, liquid phase chromatography, liquid chromatography-mass spectrometry and the like. The related biological samplescan be at least one kind of materials in blood, urine, saliva and hair. Since the interface factors of biological samples are many, the pretreatment process of inspection materials is very important.Through a great number of experiments, the mCPP in the biological samples can be sufficiently extracted through the solid phase extraction process; the efficient qualitative and quantitative analysisis realized. Each analysis method has high sensitivity and wide linear range; the detector cost is low; the automatic analysis operation is facilitated.

The invention discloses a cannabinoid active substance detection method based on an intracellular free Ca<2+> concentration change effect and a cannabinoid active substance detection kit. The detection kit comprises two components including a detection group reagent and a negative control group reagent, the detection group reagent comprises a monoclonal cell line CB1 / 293 stably expressing a human-derived cannabinoid receptor CB1 gene and an intracellular free Ca<2+> probe reagent Fluo 3-AM; the negative control group reagent comprises the monoclonal cell line CB1 / 293 stably expressing the human-derived cannabinoid receptor CB1 gene, the intracellular free Ca<2+> probe reagent Fluo 3-AM and a cannabinoid receptor antagonist. With the adoption of the detection method, accurate, high-sensitivity and rapid detection of all cannabinoid active substances including natural cannabinoid and synthetic cannabinoid as well as novel synthetic cannabinoid active substances which emerge in endlesslycan be realized, and the problem of difficulty in supervising cannabis psychoactive substances can be solved.

The invention discloses a detection method of a new psychoactive substance BZP. The method for accurate and efficient determination of BZP in a biological sample includes gas chromatography-mass spectrometry, gas chromatography, liquid chromatography, liquid chromatography-mass spectrometry and other qualitative and quantitative analysis techniques. Due to a lot of interference factors in the biological sample, the pretreatment process of the inspected material is very important. Through a large number of experiments, and by a solid-phase extraction process, the BZP in the biological sample can be fully extracted, and high-efficiency qualitative and quantitative analysis can be achieved. The analytical methods have high sensitivity and wide linear range, and the detector is low in cost, thus being conducive to automatic analysis operation.

The invention relates to a non-therapeutic application of miR-212 to regulation of DAT (dopamine transporter) gene expression in cells, and further relates to a non-therapeutic method for regulating the DAT gene expression in the cells. The method comprises the step of increasing or reducing the amount of miR-212 in the cells. The invention further relates to an application of miR-212, a miR-212 enhancer or a miR-212 attenuator to preparation of a drug for regulating dopamine uptake of the cells, and further relates to an application of miR-212, the miR-212 enhancer or the miR-212 attenuator to preparation of a drug for treating psychoactive substance addiction.

The invention discloses a detection method for opioid active substances based on a cell dopamine release effect and a detection kit for the opioid active substances. The detection kit comprises two components of a detection group kit and a control group kit, wherein the detection group kit comprises a monoclonal cell line MOR1 / SK-N-SH for stably expressing a human mu-type opioid receptor MOR1 geneand an ELISA detection kit; and the control group kit comprises a blank control cell line Neo / SK-N-SH and an ELISA detection kit. According to the detection method and the detection kit, accurate andhigh-sensitivity rapid detection of the opioid active substances, whether natural opioid products or synthetic opioid molecules comprising endless novel synthetic opioid active substances such as fentanyl and various derivatives thereof, can be realized, and a problem of difficulty in supervision of novel synthetic opioid psychoactive substances can be solved.

The invention discloses a medicinal application of carmustine, namely application of carmustine in preparation of products for preventing and / or treating psychoactive substance dependence and relapse. A pharmacodynamic test result indicates that after 30mg / kg carmustine is injected through vein, the self-administration relapse of a morphine-induced rat can be effectively inhibited, and the spontaneous activity level of the rat is not influenced, so as to prove that the carmustin has application value in clinical prevention and treatment of psychoactive substance dependence.

The invention provides a preparation route for a vilazodone hydrochloride crystal form XI: vilazodone hydrochloride with the crystal form XI is obtained by a series of operations such as dilution, pHregulation, crystallization and drying, and the problem that the crystal form XI cannot be obtained by the route of the prior patent. The drug is used for treating or preventing depression, anxiety, bipolar disorder, mania, dementia, mental disorders associated with psychoactive substances, sexual dysfunction, eating disorder, obesity, fibromyalgia, sleep disorder, psychosis-like mental disorders,cerebral infarction, tension, side effects in hypertension treatment, brain diseases, chronic pain, acromegaly, hypogonadism, secondary amenorrhea and premenstrual syndrome.

The invention discloses a detection method of a new psychoactive substance 5, 6-MDAI (5, 6-diphenylmethane diisocyanate). The detection method comprises gas chromatography-tandem mass spectrometry, gas chromatography, liquid chromatography-tandem mass spectrometry, liquid chromatography and the like, and is suitable for detection of 5, 6-MDAI in in-vitro detection materials including solid, liquidand biological sample detection materials including blood, urine, saliva, hair and tissues. The qualitative and quantitative detection method of the new psychoactive substance 5, 6-MDAI provided by the invention is simple to operate, high in sensitivity, wide in instrument selection range, wide in detection concentration range and accurate in qualitative and quantitative result, and the uncertainty range caused by nonuniform samples can be obviously reduced.

The invention discloses a pretreatment method for detecting cannabinoid new psychiatric active substances in grease. By combining the method with technologies such as high performance liquid chromatography, gas chromatography, high performance liquid chromatography-mass spectrometry and the like, cannabinoid can be better extracted and separated from a grease sample, the detection of cannabinoid in grease is realized, and the operation is simple, quick, accurate and reliable.

The invention discloses an isotope psychoactive substance labeling compound as well as a preparation method and application thereof, and the isotope psychoactive substance labeling compound provided by the invention can be used for an internal standard for determining the content of a psychoactive substance N-(3-methyl-butyramide-2-yl)-1-(p-fluorobenzyl)-indole-3-amide in a hair sample. The method comprises the following steps of carrying out qualitative detection on the N-(3-methyl-butyramide-2-yl)-1-(p-fluorobenzyl)-indole-3-amide according to the retention time and ion pair matching, and specifically, carrying out quantitative detection on a corresponding compound according to a chromatographic peak area of the N-(3-methyl-butyramide-2-yl)-1-(p-fluorobenzyl)-indole-3-amide. When the isotope labeling compound is used as an internal standard substance, the matrix effect of a detected material can be reduced, and the isotope labeling compound has a good application prospect at the aspects of judicial expertise and the like.

The invention discloses a chromogenic test method for piperazine new psychiatric active substances, and relates to the field of identification of new psychiatric active substances. According to the method, a Simmental reagent, a vanillin reagent, a Markov reagent and a nitric acid-sulfuric acid reagent are used for carrying out chromogenic reaction on known types of piperazine new psychiatric active substances, a chromogenic test screening program diagram is established, and according to the chromogenic test screening program diagram, The four chromogenic reagents are used for identifying thetypes of piperazine new psychiatric active substances of unknown types to be detected. The chromogenic test method for 22 piperazine new psychiatric active substances is established, is simple and convenient, uses few reagents, does not need to use large-scale equipment and complex instruments, and only needs to prepare four chromogenic reagents (a Simmental reagent, a vanillin reagent, a Markov reagent and a nitric acid sulfuric acid reagent) in advance; 22 piperazine new psychiatric active substances can be quickly detected on site by using a test tube, a beaker, a glass slide, a white porcelain plate or a thick white paper plate.

The invention discloses an isotope psychoactive substance labeled compound and a preparation method and application thereof. The isotope psychoactive substance labeled compound can be used for an internal standard for measuring the content of a psychoactive substance 2-(1-(5-fluoropentyl)-indole-3-amide)-3,3-dimethyl methyl butyrate in a hair sample. 2-(1-(5-fluoropentyl)-indole-3-amide)-3,3-dimethyl methyl butyrate is subjected to qualitative detection according to the retention time and ion pair matching, and specifically, corresponding compounds are subjected to quantitative detection according to the chromatographic peak area of the 2-(1-(5-fluoropentyl)-indole-3-amide)-3,3-dimethyl methyl butyrate. When the isotope labeled compound is used as the internal standard substance, the matrix effect of a detected material can be reduced, and the isotope psychoactive substance labeled compound has a good application prospect in the aspects of judicial expertise and the like.

The invention discloses a method for detecting new psychoactive substance MeOPP. The precise and efficient method for determining the MeOPP in biological samples includes qualitative and quantitativeanalysis methods such as gas chromatography-mass spectrometry, gas chromatography, liquid chromatography and liquid chromatography-mass spectrometry; the biological samples involved may be at least one of blood, urine, saliva and hairs. Due to the large number of interfering factors in the biological samples, the pretreatment process of the samples is very important. The MeOPP in the biological samples can be effectively extracted by the solid phase extraction process according to a large number of experiments, and high-efficiency qualitative and quantitative analysis is realized. Each analytical method has high sensitivity and a wide linear range. The cost of a detector is low, and the method facilitates automated analytical operation.

The invention provides a method for removing psychoactive substances in sewage. Specifically, the invention provides a flocculation and photocatalysis cooperated removal method, which comprises the following steps: firstly, mixing sewage containing psychoactive substances with a flocculant, and carrying out flocculation to obtain a mixed solution; then mixing the mixed solution with a photocatalyst, irradiating under ultraviolet light, and carrying out photocatalytic removal; wherein the mental active substance is selected from the following group: ketamine, norketamine, cocaine, benzoyl ekangning, methylamphetamine, amphetamine, or a combination thereof. The method provided by the invention can be used for simultaneously removing various mental active substances and has an excellent removal effect.

The invention relates to medicine and is directed at developing means and methods for narcological practice and for preventive measures in order to reduce the risk of falling sick with such menacing modem diseases like dependence diseases, in particular alcoholism, narcomania and toximania. Said invention provides for using already known chemical compounds, i.e. vicinal dithioglycols for developing medical agents exhibiting properties for preventing contraction or development or reducing the speed of pathological processes forming a base for dependence diseases, in particular withdrawal syndromes. The inventive substances reduce or block pharmacological effects resulting from ethanol injection and / or narcotics, thereby directly influencing pathogenic mechanisms of the dependence diseases, in particular alcoholism. It is stated that said agents are particularly efficient when they are perorally administered. Said invention is accompanied by experimental material which proves the large perspective of the inventive agents and of a prophylactic method which provides for the use thereof before and after consuming alcohol-containing beverages or narcotics. The use of the invention makes it possible to reduce the degree of falling sick with alcoholism and narcomania and to reduce the toxic action of alcohols during the household use thereof.

The invention discloses a chromogenic test colorimetric card for new psychiatric active substances and a design method thereof, and relates to the field of detection of the new psychiatric active substances. The colorimetric card provided by the invention integrates a color development result map obtained after multiple color development reagents react with multiple new psychoactive substances oneby one. The new psychoactive substances comprise 15 substances such as etizolam, flubrozepam, clozepam, fennazepam and the like. The chromogenic reagent comprises a formaldehyde-concentrated sulfuricacid reagent, an improved formaldehyde-concentrated sulfuric acid reagent, a 5% ferric sulfate reagent, a nitric acid sulfuric acid reagent, a gallic acid reagent, a Simmental reagent, a sodium nitroprusside reagent, a hydroxamic acid reagent, a vanillin reagent and a copper sulfate reagent. By means of the technical scheme, the 15 kinds of new psychoactive substances can be subjected to color development only by preparing the 10 kinds of color development reagents in advance and utilizing a test tube, a beaker, a glass slide, a white porcelain plate or a thick white paper plate, and a colordevelopment result is compared with a colorimetric card, so that criminal investigation technology inspectors can preliminarily screen suspicious new psychoactive substances on site.